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iii)  Executive Summary 
 
Novartis International AG is a well known multinational company who is ranking number two in sales 
among the worldwide Pharmaceutical industry. Now, in the current year 2012, prediction goes that it is 
going to top Pfizer and take the top rank in global Pharmaceuticals. Novartis (Bangladesh) Limited had 
started its operation officially in 1997 but the local competition is so enormous that they are not in the 
top ten rank in Bangladesh. Their slogan is “Care and cure” and by that, they are emphasizing more on 
the welfare, benefits and safety of the people. 
 
Aclasta is one of the special products of Novartis which is prescribed to cure osteoporosis. 
Osteoporosis is basically a bone loss disease where bone becomes weak and causes fractures 
afterwards. It is the first original medicine which contains Zoledronic Acid and is known as a 
revolutionary medical discovery for osteoporosis because of it’s once a year treatment. The infusion of 
the drug is pretty expensive but it’s effective as well. 
Among all the projects, Aclasta has been chosen for preparing the internship report because the 
organization allowed me to disclose the results of this report. One of the answers of research questions 
that the organization was looking for was whether the patients who are taking Aclasta reinfusion are 
finding the drug effective or not. They wanted to know the exact reason that whether the patients are 
taking the reinfusion because they are really satisfied with the outcomes or they are being compelled to 
take it by the doctors. Due to prices and other factors, Patients may not like to the infusion further. So 
the research has been done to find out the answer of those questions.  
  
For this, a questionnaire has been made and through telephone survey, patients had been asked by the 
team to give a feedback to those questions. After getting their answers, all the data has been sorted out 
and through SPSS, analysis has been done. Under one major hypothesis, 17 sub hypotheses has been 
made and then it was compared with other variables to find out associations and difference. Many 
methods have been used such as, Chi-Square test, regression, cross tabulations etc. Then after the 
analysis; the result has been interpreted and it was concluded with some findings and 
recommendations.  Finally, the answer that has been found is that the patients are satisfied with Aclasta 
reinfusion so they are taking it; they are not being compelled to take it. 
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CHAPTER ONE 
PART ONE: HISTORICAL BACKGROUND & FOUNDATION 
1.1.1 Historical Overview 
Pharmaceutical Industry is one of the highly sophisticated industries in Bangladesh which has 
been uncovered to rapid change and made a revolution in Bangladesh by maintaining high 
technology and a world class standard in quality. These industries have a major commitment to 
the society than any other industries as it is involved with the manufacturing of life saving drugs. 
Novartis (Bangladesh) Limited is one of the leading global pharmaceutical companies in 
Bangladesh. Novartis International AG, a Swiss company is the parent of Novartis (Bangladesh) 
Ltd. This company came into existence in 1997. Previously this company was known as Ciba-
Geigy (Bangladesh) Ltd. with the global merger between Ciba-Geigy and Sandoz in 1997, 
Novartis Bangladesh was formed. Novartis International AG is the mother company of Novartis 
(Bangladesh) Limited. It is now positioned as the fifth largest among all the pharmaceutical 
companies in the world. 
Novartis has been operating in Bangladesh since 1968. At that time, it was only a trading house. 
It started doing health care business in Bangladesh since 1973 again in the form of trading. In 
1979, company decided to invest in developing its own crop protection formulation plant in 
Chittagong. Novartis (Bangladesh) Limited registered with the joint  Stock company as Ciba-
Geigy (Bangladesh) Limited in 1973 a joint venture agreement between Ciba-Geigy AG, 
Switzerland (60%) and Bangladesh Chemical Industries Corporation (40%). The partnership 
with BCIC was further strengthened in 1989 with the setting up of a pharmaceutical plant in 
Tongi. Proportion of partnership remains same. The pharmaceutical plant has the success of 
developing innovative analytical methods, which have been incorporated in the Novartis 
Generics global manufacturing processes. The plant is an approved global supply point for solid 
dosage forms of Novartis Generics. Products manufactured from this plant are exported to Asia 
Pacific, European and Latin American countries. The Bangladesh Novartis is limited to the 
business of research pharmaceuticals brand. 
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Pharmaceutical industry not only meets the maximum demand of our country but also export 
these products to other countries. Bangladesh is the only country, which is self reliant in 
medicine in this part of the world beside India, which exports pharmaceutical raw materials too. 
1.1.2 Novartis principles 
 
 
 
 
 
 
 
1.1.3 Corporate Purpose 
Novartis corporate purpose is to discover, develop and successfully promote innovative products 
to cure diseases, to ease sufferings and to enhance the quality of life. They want to create and 
successfully commercialize leading products to treat patients, to prevent disease and to restore 
the life of people. The company also wants to provide a broad portfolio of innovative, effective 
and safe products and services to patients through healthcare professionals around the world. It 
tries to meet the essential needs of people everywhere. 
Their long-term success requires a total commitment to exceptional standards of performance 
and productivity, working together effectively and a willingness to embrace new ideas and learn 
continuously. They believe that success requires the highest standards of corporate behavior 
towards their employees, consumers and in the society they live. This is Novartis road to retain 
                                     Several product categories. Various brands 
I provide effective and quality product; Innovative new products 
Innovation is the heart of our research strategy 
I am committed to focus on research and development 
I span the country covering thousands of medicine outlets 
To provide a broad portfolio of innovative, effective and safe products and services 
to patients through healthcare professionals around the world 
Our purpose is to improve lives; to extend lives; to save lives. 
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sustainability, profitable growth and long-term value creation for their shareholders and 
employees. 
1.1.4 Vision 
 
 
 
1.1.5 Mission Statement 
I, Novartis Bangladesh, guided by our Aspirations believe in ensuring our long term existence by 
being profitable and sustainable with our commitment to providing value adding innovative 
products and services to satisfy the needs of our customers in the sectors of: 
 Pharmaceuticals 
 Sandoz 
 Animal Health  
1.1.6 Goal  
They aim to harness the latest advances in biomedical research and technology to develop new 
therapies with the potential to benefit millions of patients throughout the world. 
PART TWO: NOVARTIS-AT A GLANCE 
1.2.1 Glimpse of Global Novartis 
Basle, the Chemical Capital of Switzerland is famous for its four-way culture for placing the 
border of four countries and for its four large chemical companies because of its geographic 
position, Basel had a great opportunity to prosper.  
To be a global leader in the discovery, development and 
commercialization of pharmaceuticals 
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First there are three companies: Geigy which history goes back to the middle of the 18th century, 
Ciba, born at around 1860 and Sandoz which was set-up in 1886. The three most famous 
chemical companies are:  
Ciba: Chemical industries of Basel 
Geigy: Named after the owner J. R. Geigy 
Sandoz: Health care specialist 
In 1970 Ciba and Geigy merged. The newly created Ciba-Geigy Ltd. and Sandoz continued to 
follow separate ways for two and a half decades. 
On March 7, 1996, It has been formally announced that, Sandoz and Ciba, two proud Swiss 
based companies with almost three hundred years of tradition, agreed to integrate to become one. 
The creation of Novartis was at that time one of the largest corporate merger in the history. Ciba-
Geigy Ltd. and Sandoz both have a colorful and rich history spanning more than hundred years. 
Preceding the merger, there are months of top-secret negotiations and meetings of the minds on a 
bold strategic move.   
Novartis is the world leader in research and development of products to protect and improve 
health and ill being. The very name derived from the Latin novae artes, meaning new skills 
reflects its commitment to focus on research and development to bring innovative new products 
to the society. Novartis wants to have a positive impact on people‟s lives and to discover, 
develop and successfully market innovative products to cure disease and enhance the quality of 
life. 
With the approval of the EU and US Federal Trade Commission, Novartis finally came into 
existence on December 20, 1996, clearing all the regulatory hurdles of the merger. 
Headquartered in Basel, Switzerland, Novartis innovates for the benefits of its customers. It 
operates through 360 affiliates in 140 countries and offers its products through its 
Pharmaceuticals, Generics, consumer Health, CIBA Vision, Animal Health and Business 
Development & Licensing Unit.  
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1.2.2 Brief Profile of Novartis 
   
Type Public 
Industry Pharmaceutical Industry 
Business Segments  Pharmaceuticals,  
 OTC Drugs,  
 Vaccines & Diagnostics,  
 Generics,  
 Animal-Health Medicines,  
 Contact Lenses & Lens Care 
Products 
Founded 1996 (from Merger) 
Headquarter Basel, Switzerland 
Number of Countries Operating in 140 Countries 
K
ey
 P
eo
p
le
 
Chairman, Board of  Directors Dr. Daniel Vasella 
Chief Executive Officer Joseph  Jimenez 
Chief Financial Officer Jon Symonds 
Division Head, Pharmaceutical David Epstein 
MD, Global Head, Novartis Institute for 
BioMedical Research 
Dr. Mark Fishman 
Division Head, Generics Jeff George 
Division Head, Consumer Health George Gunn 
MD, Division Head, Vaccines & 
Diagnostics 
Dr. Andrin Oswald 
Global Head, Human Resources Jurgen Brokatzky-Geiger 
General Counsel Dr. Felix Ehrat 
 Corporate Secretary Dr. Charlotte Pamer-Wieser 
 Chief Compliance Officer Dr. Peter Kornicker 
Healthcare Revenue US $ 44.27 Billion (2011 - Jan 25, 2012) 
Consolidated Revenue US $ 44.27 Billion (2009) 
Operating Income US $ 10,998 Million (2011 - Jan 25, 2012) 
Net Income US $ 9,245 Million (2011 - Jan 25, 2012) 
Earning Per Share  US $ 3.83 (2011 - Jan 25, 2012) 
Total Assets US $ 95.51 Billion (2009) 
Shareholder‟s Equity US $ 57.46 Billion (2009) 
R&D Expenditure US $ 7.47 Billion (2009) 
Associates 1,20 ,000 Associates 
Net Sales US $ 58,566 Million (2011 - Jan 25, 2012) 
Subsidiaries Sandoz, Ciba Vision 
Official Website and Information Source www.novartis.com 
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1.2.3 Global Financial Performance 
At present, Novartis holds the 4
th
 place in the top 50 pharmaceutical companies all over the world with 
USD 44.3 billion revenue, USD 10.3 billion net income and USD 7.5 billion Investment in R&D. On the 
basis of financial performance Johnson & Johnson holds the leading position succeeded by Pfizer, Roche, 
and GlaxoSmithKline. In addition, Novartis also holds 184
th
 position in „Fortune 500 Company‟ ranking. 
The following chart (1.2.3) shows the position of Novartis from the global perspective: 
Chart 1.2.3: Global Financial Performance of Novartis    
 
 
 
 
 
 
 
(Source:  Med News, September 2010, Volume 29, Number 9) 
1.2.4 Top 3 R&D Based Companies & Novartis Position 
Evaluate Pharma‟s World Preview 2018 reveals that It is being forecasted that Novartis is going 
to be the biggest seller of drugs by 2018, it is also expected to be spending the most on 
developing them,  . The Swiss pharma giant is investing $10.1billion on pharmaceutical R&D by 
2018 when most other major companies are cutting back. Novartis spent $135bn on research in 
2011, equivalent to 18.8% of worldwide prescription drug sales.  
(Source: http://www.epvantage.com/Universal/View.aspx?type=Story&id=302035&isEPVantage=yes) 
On the basis of research and development expense, Novartis holds the 3
rd
 position globally. 
Roche holds the leading position while Pfizer is on the second place. The following chart shows 
the R&D expenditure of these top three companies in 2008 and 2009: 
41459
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7217
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  7 
Chart 1.2.4: Top 3 R&D Based Company’s R&D Expenditure 
 
Source: Med News, September 2010, Volume 29, Number 9 
1.2.5 Best-Selling Rx Products of Novartis 
Globally the 10 best-selling Rx products of Novartis of 2009 and 2008 are as follows: 
Table 1.2.5: Best-Selling Rx Products of Novartis 
Product 
Sales ( US $ Million) 
    2009       2008 
Diovan, Diovan HCT 6013 5740 
Gleevec/ Glivec 3944 3670 
Zometa 1469 1382 
Femara 1266 1129 
Lucentis 1232 886 
Sandostatin 1155 1123 
Exelon, Exelon Patch 954 815 
Neoral, Sandimmun 919 956 
Volteren group 797 814 
Exforge 671 406 
Source: Med News, September 2010, Volume 29, Number 9 
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Novartis (2010) 
  
Headcount                          119,418 
Year Established               1996 
Pharma Revenues                   $44,420           16% 
Total Revenues                       $50,324           14% 
Net Income                        $9,969             18% 
R&D Budget                      $8,080             11% 
  
Table 1.2.5.1: Top-Selling Drug of Novartis in 2010 
 
Drug Indication $ (+/- %) 
Diovan hypertension $6,053 1% 
Gleevec chronic myeloid leukemia $4,265 8% 
Lucentis age-related macular degeneration $1,533 24% 
Zometa bone metastasis $1,511 3% 
Femara breast cancer $1,376 9% 
Sandostatin Group acromegaly $1,291 12% 
Exelon Alzheimer‟s disease $1,003 5% 
Exforge hypertension $904 35% 
Neoral immunosuppression $871 -5% 
Voltaren inflammation/pain $791 -1% 
Exjade iron chelation $762 17% 
Comtan Parkinson‟s disease $600 8% 
Reclast osteoporosis $579 23% 
Source: Med News, September 2010 
  
 
PART THREE: CODE OF CONDUCT 
1.3.1 Code of Conduct 
Novartis adopted its first global Code of Conduct in 1999. In order to reflect the signing of the 
Global Compact in 2000, an amendment became necessary. The revised version of the Code of 
Conduct was distributed in 2001 to all Novartis Group company employees worldwide and 
translated into local languages. Compliance with our Code of Conduct, which is a part of the 
employment terms of all Novartis employees, is closely monitored. For this Novartis have 
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established a worldwide network of over 45 Compliance Officers who advise on compliance. 
The Code of Conduct is an expression of the professionalism Novartis strive for throughout our 
businesses, and of the professionalism I expect of our associates. 
As an ethically, socially and ecologically responsible organization, Novartis places a premium on 
dealing fairly with employees, commercial partners, government authorities and the public. 
Success in its business ventures depends upon maintaining the trust of these essential 
stakeholders. 
Code of Conduct is fundamental to the task of creating and Novartis considers this Code of 
Conduct to be essential in its relations with its employees. It shall form an integral part of the 
terms of employment of the companies of the Novartis Group. Novartis will insist on full 
compliance. 
The standards are based on:  
 Support of and respect for the protection of internationally 
 Proclaimed human rights 
 Ethical and legal behavior 
 Loyalty to Novartis 
 Fair, courteous and respectful treatment of fellow employees 
 Fair and appropriate consideration of the interests of other stakeholders (customers, other 
commercial partners, government authorities and the public) and of the environment 
 Professionalism and good business practice 
 Our commitment to the Global Compact 
PART FOUR: NOVARTIS (BANGLADESH) LIMITED 
1.4 .1 Milestones of Novartis Bangladesh 
 1973-Registered with a joint stock company as Ciba-Geigy (Bangladesh) Limited. 
 1979-Jont-venture agreement between Ciba-Geigy AG, Switzerland (60%) and 
Bangladesh Chemical Industries Corporation (40%) 
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 1997-Ciba-Geigy become Novartis (Bangladesh) Limited 
 A global merger of Ciba and Sandoz 
 The Bangladesh Novartis has its chief manufacturing plant in Tongi. This very plant was 
inaugurated at Tongi in 1989. This plant not only meets the local market needs and 
demand, but exports product to countries in Asia pacific, Latin America, and Europe as 
Ill. Total export in 2001 was BDT 37.0 MIO. 
1.4.2 Location    
Novartis (Bangladesh) Limited 
Head Office 
House 50, Road 2A 
Dhanmondi RA, Dhaka 1209 
GPO Box 431 
Dhaka 1000 
Bangladesh 
Tel:  + 880 2 861 5302-8 
 
Novartis (Bangladesh) Limited 
Production Plant 
Squibb Road 
Cherag Ali Market 
Tongi I/A, 
Gazipur 
Bangladesh 
Tel: + 880 2 980 0561-4 
1.4.3 Distribution Center   
Starting out in Asia over 60 years ago, Zuellig Pharma has established itself as the leading 
healthcare distribution solution specialist in the region serving 15 countries and regions in Asia. 
Zuellig Pharma Bangladesh Limited was incorporated in June 2006 as it continued its expansion 
into South Asia establishing its Corporate Office in the Gulshan area of Dhaka. Zuellig Pharma 
operates as a distribution house for Novartis Bangladesh which has a countrywide distribution 
network having 13 branches. The branches are in the following cities in all over the country:  
 Dhaka 
 Chittagong 
 Comilla 
 Sylhet 
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 Mymensing 
 Maizdee 
 Khulna 
 Barisal 
 Rajshahi 
 Rangpur 
 Bogra 
 Jessore 
1.4.4 Manufacturing Plant of Novartis (Bangladesh) Limited  
Manufacturing Plant of Novartis (Bangladesh) Limited has been inaugurated at Tongi in Gazipur 
zone in 1989. This particular production Plant meets the need of the local customers as well as 
exports to countries in Asia-Pacific, Latin America, and South Africa. This plant produces 200 
million tablets per year to meet both the local and international need of the customers.  
Recently Novartis has set up a new plant to meet the growing export demand in various countries 
including the whole Europe, according to the new target plan of 2002. Both the plants are 
expected to produce 400 millions of tablets, which is double the previous amount, to satisfy the 
customers demand delicately.   
1.4.5 Organizational Structure    
In terms of Novartis, they have one chairman and CEO leading the company worldwide. They 
have five Head leading five different Business Units. They have divided their worldwide 
business into different region and have different business groups to manage them.   Apart from 
that no further information could be gathered about the organizational structure of Novartis.  
Novartis Bangladesh, falls under the Southeast Asian region. It has one Chairman and one 
Managing Director (MD) under the board of the company. There exist one Chairman, one 
Managing Director (MD), three Alternative Directors and the Company Secretary as the Board 
Members. Two Directors from BCIC are also there in the Board. 
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The last Novartis MD was the first Bangladeshi Managing Director of the company who has 
become the MD of Novartis (Bangladesh) Limited, in July 2002. The company also has a CEC 
or Corporate Executive Committee consists of the Managing Director, three Alternative 
Directors. 
PART FIVE: MARKET SCENARIO OF NOVARTIS (BANGLADESH) LIMITED 
1.5.1 Key Challenges 
 Primary role is to discover, develop and successfully market innovative products to cure 
diseases, to ease suffering and to enhance the quality of life. 
 To ensure that humanity continues to benefit from pharmaceutical innovation. 
 To define an equitable way for sharing the economic burden of pharmaceutical 
development among the various segments of society. 
 To ensure that research, development and application of pharmaceuticals are conducted 
in harmony with society's ethical and cultural standards. 
 Other key challenges include the issues of marketing practices, animals used in research 
and development, and accountability for our suppliers and contractors. 
 The latest challenge for Novartis (Bangladesh) Limited facing is about OTC. OTC is in 
loss for last one the Business Unit is in loss. By making the business unit again profitable 
is an extreme challenge for NBL. 
1.5.2 Problem Faced by Novartis 
 In case of cost curtail, it is not possible since all the raw materials are outsourced from 
outside Bangladesh, which are highly expensive. Thus prices of all the products are very 
high and Novartis faces a tremendous competition with the local companies regarding 
price set. 
 Due to complex Government regulations and rules are imposed, the raw materials have to 
be stored in inventory for a long time which increases the price of the product naturally 
and helped other medicine to capture the market. Thus Novartis is left with a limited 
number of end users.  
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 Novartis cannot follow any Cost Leadership Strategy. For a company like Novartis, who 
has to spend so much on Fixed Overhead Cost and Variable Overhead Cost, it is 
impossible to be cost effective while producing.  
 Novartis face a lot of problems while having any legal agreement, or signing any contract 
with the government bodies and authorities. But local companies do not have to face 
these hassles due to relaxed laws, rules-regulations and their continuous Rent Seeking 
Behavior in this arena. 
 Lack of practice of patent law in Bangladesh, makes it all the more difficult for MNCs to 
exist and compete with the local companies who do not follow much of these laws. 
 Keeping a high price in Primary Care product market (mainly in research related 
products) makes it harder to compete and survive in the local market. 
 Doctors, the customer group, expects more frequent visit of the field force, which is 
difficult to maintain and continue. 
 Hard to meet the demand of the local market for generics product in case of Primary Care 
and Generics product while competing with the local companies. 
 After globally selling out some products, which Ire profit generating products for 
Bangladeshi market from OTC, this BU‟s sales drop down in Bangladesh. One of the 
major products of them was Ovaltin, which is sold to Nestle. Loss in OTC is a key 
problem from NBL. 
1.5.3 SWOT Analysis 
This analysis will give a picture of the competitiveness of this company in comparison to that of 
its competitors. 
Strengths 
 Modern Technology and know-how 
 It is a huge MNC providing quality product 
 A widely recognized company with an attractive customer base 
 A proven track record in defect-free manufacture 
 Expertise in providing consistently good customer service 
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 Skills in producing innovative products 
 Highly Efficient employees 
 Job flexibility for employees thus company has a group of loyal employees. 
 Proprietary technology and important trade mark 
 Very attractive remuneration package as well as fringe benefits for employees 
 Effective State-of-the-art plant and equipments 
 Available Cash on hand 
 An experienced and capable workforce 
 Highly Experienced and efficient employees in key areas 
 Motivated employees 
 Managerial know-how 
 Long term collective learning and know-how 
 A strong balance sheet 
 Company reputation 
 A positive work climate and organization culture  
 Novartis is the number 1 ethical pharmaceutical company worldwide. 
 Novartis is in 2nd position among all the industries globally. 
Weaknesses 
 Very expensive Raw Materials 
 Low cost manufacturing know-how 
 A company Intranet for accessing and exchanging information both internally which 
might create a problem in time of need. 
 Countrywide distribution network is not as strong as competitors 
 Losing Business Unit, OTC. 
Opportunities 
 Serving additional customer group in the existing geographical market. 
 Expanding into new geographic markets. 
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 Strength in export oriented products. 
 Expanding the company‟s product line to meet a broader range of customer needs 
 Transferring sector‟s skill or technological know-how to a new business or a new 
product. 
Threats 
 entry of the possible new competitors 
 Growing bargaining power of suppliers. 
 Adverse shift in foreign exchange rate 
 expensive new regulatory obligations 
  Pharmaceutical company in Bangladesh cannot have patent right of drugs because of the 
TRIPS agreement. Therefore Novartis will be facing threat to bring patented molecules of 
Novartis Pharmaceuticals. 
1.5.4 Sales and Growth Movement 
Novartis is getting benefitted from a regular growth in pharmaceutical market which is even 
unusual in the case of the market leader of the industry. The following chart (1.5.4) proves the 
fact where it shows the sales and growth trend of Novartis in Bangladesh market from 2007 to 
2011. Novartis has shown tremendous growth from 2010 to 2011. Its growth has become double 
within a year. 
Chart 1.5.4: Sales & Growth Trend of Novartis Bangladesh from 2007 to 2011 
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1.5.5 Market Share 
The pharmaceutical market of Bangladesh is dominated by local companies so global companies 
have to face certain obstacles in operating their business. In this situation, the market share of 
Novartis is still moving upward that is illustrated in the following chart (1.5.5).       
Chart 1.5.5: Market Share of Novartis Bangladesh from 2007 to 2011 
 
 
Source: Bangladesh Pharmaceutical Index, IMS, 2011 (Company Subscribed Software)  
1.5.6 Top 5 Brands of Novartis in Bangladesh Market 
The five best selling brands of Novartis this division are shown up here. The following chart 
(1.5.6) illustrates the sale of both 2009 and 2010.    
Chart 1.5.6: 2 Years Sales Trend of Top 5 Brands of Novartis Bangladesh 
 
 
  
 
 
 
 
Source: Bangladesh Pharmaceutical Index, IMS PLUS 2Q, 2010 (Company Subscribed Software) 
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CHAPTER TWO: JOB OVERVIEW 
2.1 Objective  
To complete the BBA (Bachelors of Business Administration) program, it is mandatory to do 
internship in an organization or to submit a project report. Internship enables business students to 
furnish the practical and realistic ground of the work field. Internship phase is basically for three 
months but it can be extended if the organization and the student want. However, as per the rules, 
I have done my internship in Novartis (Bangladesh) Limited.  
So my specific objective is to: 
 Complete the BBA Program 
 Boast a handy job experience 
 Introduction with the corporate environment 
 Observe and learn as much as possible from the senior associates. 
2.2 Division where I have worked in: 
Novartis has five different Business Units. Following Business Units are operating under 
Novartis Bangladesh:  
 Pharmaceutical Division is headed by the Country Pharma Organization of Pharma 
Division. General medicine (Mass market products, Specialty products, Vaccine & 
Ophthalmic) & Oncology are two units of the division. This division completely works as 
a MNC 
 Generics Business Units, Sandoz, headed by the BU Head of the business unit. OTC is 
currently under Sandoz. this division follows and works as local Pharmaceutical 
Company 
 Animal Health Business Unit executed by BU head of Animal Health unit.  
I have done my internship in Novartis Pharmaceutical division. 
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Primary Care
Oncology
TransplantationOphthalmic
Mature Product
2.2.1 Overview: Novartis Pharmaceuticals  
Novartis goal is to provide a broad portfolio of innovative, effective and safe products and 
services to patients through healthcare professionals around the world. At Novartis 
Pharmaceuticals innovation is the heart of their research strategy. They aim to harness the latest 
advances in biomedical research and technology to develop new therapies with the potential to 
benefit millions of patients throughout the world. Past sixth consecutive years, Novartis 
Pharmaceutical division has been achieving double-digit sales growth as net sales rise 11%, with 
the cardiovascular and oncology businesses being the main drivers.  
In 2005-2006 Novartis introduced some global brands: Co-Diovan, Lescol XL, Voltalin Forte, & 
Trileptal. Now Diovan is the global number one antihypertensive. So, with this sort of 
introduction Novartis tried to be with its key commitments to the society. The post 2000 scenario 
of Novartis activities talks in favor of its dynamic attitude in terms of new introduction & line 
extension. Elidel, Zelnorm/Zelmac, new indications for Zometa, Diovan, Visudyne, 
Gleevec/Glivec are few examples of that.  
 From 2001 to 2006, Novartis achieved double digit market growth year even in a situation of 
highly competitive generic dominated market situation, where generic companies are of 15-25 
times more Field Force strength & 5-10 times lower price.    
Novartis Pharmaceuticals is comprised of five business units. They are: 
Figure 2.2.1.1: Five Business Units of Novartis Pharmaceutical Division 
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2.2.2 Description of Various Departments  
Novartis Bangladesh has a blend of simple and complicated departmental structure, which does 
not comply with the global Novartis. This customization has been done for the convenience of 
operation of this part of region; especially for a developing country where mass production and 
operational activities have not gone as far as developing nations.  
Novartis Bangladesh has four departments, which provide the company a common service and 
simultaneously work for all the Divisions and Business Units. These four departments separately 
do their respective jobs and activities for all the business units existing in Novartis Bangladesh.  
These departments are:  
 Human Resource Department 
 Finance & Accounting Department 
 IT or Information Technology Department 
 Distribution Department 
Apart from these four departments there are other Business Units of Novartis. They are:  
 Portfolio Management Departments 
 Medical & Drug Regulatory Affairs 
 Sales Department 
 Marketing Services Department 
 Business Planning Analyst 
The above five departments, Business Units and Divisions are also act as separate entity in the 
company, for which these four departments provides all kinds of operational activities and gives 
them continuous support in case of- 
 Networking and System failure 
 Employee lay off or Recruitment 
 Sales and Promotional campaign 
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 Employee Training and Evaluation 
 Balance sheet, Budget and Treasury 
 Yearly funding and loans 
 Keeping tracks of all kinds of legal and government regulations 
 Signing and negotiating with the Government Bodies. 
 Portfolio Management Department 
Portfolio Management department is consisted of Head of portfolio Management and ten 
Portfolio Managers who look after different product categories of Pharmaceutical division. This 
department also has quite a few Regional Managers who report to the portfolio managers 
directly. Head of Portfolio Manager and other Portfolio Managers sit together and take decision 
on various issues regarding the marketing, promotion, post marketing activities and sales of 
different medicines innovated by Novartis. The Divisional Management Team and Marketing 
Managements Team and The Sales Team sit together and take the last time decisions on various 
issues related to the marketing of the products as Ill as they take part in strategic planning and 
marketing for the Pharma Division. 
 Sales Department  
Sales team is consisted of chiefly National Sales Manager, eight Regional Manager, eight 
Medical Information Officer and two Oncologists. Under the Sales Manager works a Sales 
Operational Executive. There are eight Regional Manager under the National Sales Manager 
who reports directly to the head of the Sales Manager. There is one Medical Information Officer 
under one Regional Manager and one Oncologist specialist for each Medical Information 
Officer. There are eight sales outlet in the Sales Department overall in the country in five 
districts in the country. They are: Dhaka and greater Dhaka, Chittagong, Sylhet, Khulna, Bogra. 
Sales Operational Executive gathers and stores operation data, procures stationeries, 
miscellaneous, organizes and arranges field force work as Ill as workers and finally assists Sales 
manager. 
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 Marketing Services Department 
This is another important body of Novartis, which organizes all the events, seminars, scientific 
symposium and all sorts of meets and workshops for the company. This very department also 
takes part in the decision-making along with the division management team and marketing 
management team. Marketing Services Department consists of one Manager, Marketing services 
and three more staffs under him who help to complete the jobs on time. They keep track of all 
the expenses on a variety of staffs, elements and miscellaneous expenses carried out by the 
company. They have to keep continuous connection with all the existing departments of 
Novartis. 
2.3 Department where I have worked in 
I have worked in Compliance department. The department consists of seven people. There is 
one Medical Director and DRA head, who manage this department. Under him, there was DRA 
Manager, DRA executive, adverse event Manager, Medical Advisor and clinical research 
manager, Head of Quality compliance, Medical scientific liaison and me as intern and research 
associate.  
2.4 Job Specifications 
I have been appointed as Clinical Research Associate in Novartis (Bangladesh) Limited. I was in 
Pharma division and worked in compliance department.  My on-site supervisor was Dr. Tanvir 
Mobarak Ali, Director, Medical & Drug Regulatory Authority (DRA) and I was the associate of 
Dr. Farzana Chowdhury, Manager, Clinical Research and Medical Officer. 
During the internship phase, I was appointed with several projects. Summary of the 
specifications of those projects are given below:  
2.4.1 NP4 SOP 2012 
NP4 stands for Novartis Pharma Promotional Policies and Procedures and SOP stands for 
Standard Operating Procedure. NP4 is updated in every year. Novartis is basically a multi-
national Pharmaceutical company who is operating in 140 Countries. So basically Novartis 
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(Bangladesh) Limited have to follow the global guidelines but also they need to deal with the 
Bangladesh Drug Regulatory Committee. In NP4 SOP, fundamentals that are usually being 
updated is- 
 Rules and details of  events, funding, venue, hospitality, international event 
 Details of promotional gifts, courtesy gifts, samples 
 Non-promotional interactions with Health care professionals 
 Purpose of  Consultants / Advisory Boards / Expert meeting, Studies in humans, Market 
Research, Investigator meetings, Disease awareness programs, Disease awareness 
programs 
 GRANTS- Research / Educational grants, Educational grants relating to events, Image-
building grants 
 Interpretation and implementation of Promotional material 
 Local guidelines of organizing Scientific meetings / seminar, Round Table 
Discussions/Conferences (RTD), Promotional Gifts, Courtesy Gifts, Compensation for 
healthcare professionals, sponsorship for HCP‟s, Participation of partners (accompanying 
person) for all kind of activities, workshops and congresses, Consultants / Advisory 
Boards / Expert meeting, Any types of studies/research programs involving humans 
(post-authorization, interventional and non-interventional), Market Research, Disease 
awareness programs, Patient compliance programs, Grants. I was responsible for finding 
out the gaps, analyzing and implementing the results through updating the SOP.  Under 
the supervision, I have also prepared the clearance and approval forms.  
 
2.4.2 GALVUS: 
GALVUS is a special medicine which is only made by Novartis only for the diabetes patients. 
For the research in this product, Global team has specified a target of 510 outcomes of patients in 
Bangladesh. So per criteria, 57 famous, skilled, trained expert doctors been chosen from all over 
Bangladesh who is named as investigators for this purpose. Under their supervision, 510 patients 
are being chosen. The results are being updated through three visits and the duration of research 
is 6 months. All the outcomes that have been documented in that time are being sent to the 
manager for the last investigation in Bangladesh. 
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I was solely responsible for this project and in this project; I was in supervision of the manager. 
The report form for Galvus was called as “GUARD”. 
Works that I had to do is, 
 Finding out the deviation from the paper Case Report Form (CRF). If there is any, 
then send it to the manager for the clarifications. 
 If there is no deviation, then documenting it to the main CRF  
 After that, Main CRF is sent to the investigators for their last checking and to give 
their sign as approval. 
 After they approve, distortion of the CRF pages are being made. White pages are 
being sent to data management which is in India, Blue pages are being archived and 
yellow pages are being sent to the investigators of Bangladesh. 
 
2.4.3 ACLASTA: 
Aclasta is a drug to treat osteoporosis. I had to interpret some research results of 
ACLASTA. I was in a team of three where I worked as interpreter. I have documented 
the case report form of the Aclasta patients. The report form for Aclasta was called as  
“AZURE”. 
 
2.4.4 VIRTUE 
Virtue is another project of GALVUS which will start from July 15, 2012. To 
successfully launch the project, I was responsible to monitor all the activities including 
going to field visit to meet with the investigators. 
 
2.4.5 DCF 
DCF stands for Data Clarification Form. This basically comes from the data management 
which is in India incase of deviations and confusions that has been found in the CRF‟s. I 
was responsible to clarify the questions of DCF, make a copy of that for sending it to the 
investigators for approval and then to launch the documents back to India.  I have worked 
for the DCF of two products which is Galvus and Sebivo.  
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2.4.6 HONORARIUM 
I was responsible to monitor the honorarium of investigators, data entries for giving the 
requisition for it along with tracking, archiving all the relevant documents.  
 
2.4.7 GCP WORKSHOP 
I was a part of the team who arranged GCP Workshop. GCP stands for Good Clinical 
practice. Speaker was an expert from India, Dr. Sonal Vora and it was held in Hotel 
Ruposhi Bangla. It was a day long session with 45 investigators of Bangladesh.  
 
2.5 Relevancy of the work with academic Learning’s: 
 
In the NP4 SOP project, I had to find the breach between the global guidelines and the 
actual activities that was happening. Afterward through the meeting, proposed results 
were given to the director and whilst he approved, I was responsible with the team to 
implement those results.  This was a bit related to the course “Service Marketing” where I 
had to locate gaps and find out what can be executed accordingly. As a result that course 
helped me a lot to that project. 
 
The course, “Programming language for Business (MSC 142)” was a major aid to 
successfully complete all the projects. For all types of documentation, using Microsoft 
excel was mandatory. Hence I worked as a research associate, creating database was 
obligatory. So this course helped a lot in my practical work. 
 
Some of my projects included SPSS work. To interpret those SPSS results, the course; 
“Research methods in Business and management (BUS 302)” was simply a blessing 
because all the things that I have learned in this course were entirely related to my 
practical work. These are the courses which were fully related to my work. 
 
Indirectly, some other academic courses were also relevant to my project. “Statistics for 
business and economics (ECO 202)” was one of them. Also from the course, 
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“Organizational behavior (MGT201)”, I was actually able to relate what was happening in 
the organization with my scholarly learning‟s. 
 
2.6 Knowledge that has been enhanced : 
Some learning‟s that I have been improved through my internship period is- 
 Proper Time Management 
 Maintaining Organizational Ethics 
 Knowing the Customs and Culture of the organizations 
 Advanced computer skills 
 Proper business etiquette 
 Proper Archiving 
 Planning events and work beforehand 
 Managing stressful situations 
 Work in dynamic situations 
 Activation and supervision of work 
 Handling projects 
 Communication with clients 
 Clerical works 
 
By observing the senior colleagues, I have learned many things. It has enhanced and 
boosted up the confidence level. In this extensive training period, there were so many 
mistakes that I have done in the work and because of that, now I am able to do more error 
free work now on. 
 
2.7 Challenges 
Sometimes a little error can be a large mistake or loss for an MNC. There are some 
challenges that I have faced during my work in internship period- 
 Less skilled in clerical work 
 Misunderstanding in work 
 Mistake in communications 
 Error in follow up and documentation 
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 Unstable politics of Government 
 Sudden Projects hampers existing project plans deadline 
 Uncertainty about the upcoming 
 
2.8  Project for the internship report 
For the internship report, I have chosen one of my projects named “Aclasta-AZURE”. 
 
2.9 Reason Behind choosing ‘Aclasta’ project for the report 
Two most important projects for which I was responsible solely was NP4 SOP and 
GALVUS but both of the projects were confidential. Novartis (Bangladesh) Limited 
didn‟t allow me to disclose the works. As a result, I was unable to choose between these 
two. 
Aclasta was one of my works that I have started in the beginning of my internship. At that 
time, I had to select one of my projects and give the topic name to the academic advisor. 
So I talked to my on-site supervisor and he suggested me to give my internship project in 
one of the segments of Aclasta. As it was a project of a team, I have got many help to 
gather the data. As company allowed me to disclose the work in this project and the topic 
was approved in the university, so I decided to submit the work on this project. 
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CHAPTER THREE 
PART ONE: PHARMACEUTICAL INDUSTRY ANALYSIS 
The pharmaceutical industry as a business sector is performing really well in Bangladesh. As 
shown in the Table (3.1.1) below, the value of this market is growing on a regular basis. In 2007, 
the total sales value was approximately 42 billion whereas in 2010 which increased by 60 billion 
(BDT).  The following table (3.1.2) shows the sales as well as growth trend of the industry from 
2007 to 2010. 
Table 3.1.1: Industry Scenario from 2007 to 2010 
Year Sales in Billion (BDT) Growth (%) 
2007 41 6.99 
2008 43 4.09 
2009 51 18.35 
2010 60 17.65 
Source: Bangladesh Pharmaceutical Index, IMS PLUS 2Q, 2010 (Company Subscribed Software)  
It is found that the industry has 17.65% growth in the year 2010 and is now recognized to have 
great export potential. The total market size of Bangladesh pharmaceutical industry amounted 
Tk. 60 billion. Notably, within last four years, Bangladesh pharmaceutical industry has gone 
through with a continuous upward and downward pattern, as pointed out below: 
Chart 3.1.2: Sales and Growth Trend of Pharmaceutical Industry from 2007 to 2010 
 
Source: Bangladesh Pharmaceutical Index, IMS PLUS 2Q, 2010 (Company Subscribed Software) 
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PART TWO: COMPETITIVE SCENARIO 
SQUARE is leading the Pharmaceutical industry with 1378 Crore taka sales followed by Incepta 
Pharma with 650 Crore taka.. Among top 20 companies, POPULAR PHARMA has been 
showing tremendous growth of 54.53% last year. Top 10 companies have been observed to hold 
more than 67% market share of the industry.  
The following Table (3.2.1) portrays the overall scenario of top 19 companies of the industry in 
2011: 
Table 3.2.1: Top 19 Players of Industry in 2011 
Top Pharmaceutical Company of Bangladesh: 2011 
  
Taka (Crore) Share Growth % 
Rank Total Market 7,186 100.00 24.30 
1 SQUARE 1,378 19.18 23.54 
2 INCEPTA PHARMA 650 9.05 32.17 
3 BEXIMCO 620 8.62 40.33 
4 OPSONIN PHARMA 355 4.94 26.09 
5 ESKAYEF 348 4.84 24.82 
6 RENATA 340 4.73 29.63 
7 ACME 319 4.44 17.34 
8 A.C.I. 293 4.08 18.81 
9 ARISTOPHARMA 286 3.99 21.63 
10 DRUG INTERNATIONAL 270 3.75 18.18 
11 SANOFI AVENTIS 185 2.57 8.77 
12 GLAXOSMITHKLINE 140 1.95 10.84 
13 ORION PHARMA LTD. 140 1.94 31.47 
14 NOVO NORDISK 128 1.79 27.72 
15 HEALTHCARE PHARMA 126 1.75 33.20 
16 GENERAL 117 1.63 19.25 
17 SANDOZ 109 1.51 12.25 
18 POPULAR PHARMA 94 1.31 54.53 
19 NOVARTIS 94 1.30 46.01 
Data Source: Bangladesh Pharmaceutical Index' 1st Q, 2011 
Being the leader, Square Pharma is having the major portion of the market that is 19.18% with a 
growth rate of 23.54%. On the contrary, POPULAR PHARMA, the 18
th
 player of the industry 
has shown the highest growth rate which is more than twice than that of the industry at present 
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(industry growth is 24.30%). Novartis has shown remarkable growth rate of 46.01% (The second 
highest) though it is the 19 largest pharmaceutical company in Bangladesh. 
The detail growth of top 10 companies in 2011 has been shown in chart 3.2.2 below: 
Chart 3.2.2: Growth Trend of Top Players of 2011 
 
Source: Data Source: Bangladesh Pharmaceutical Index' 1st Q, 2011 
The following figure 3.2.3 shows the annual sales of the top players in 2010. It is seen that for 
being in the leading position, again Square Pharma is dominating the sales thus the overall 
market share (chart 3.2.3).   
                                         Chart 3.2.3: Annual Sales of Top 10 Players in 2010 
 
 
 
 
 
 
Source: Bangladesh Pharmaceutical Index, IMS PLUS 2Q, 2010 (Company Subscribed Software)  
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The major contributing factors to drive the growth of the local companies of this industry are its 
generic dominated market, new launches and absence of the use of WTO agreement. Unlike 
foreign pharmaceutical markets, local market is much more generic oriented that is shown in the 
sales pattern of the top players. Basically these local companies maintain their market share and 
growth by dealing with generic products and new launches. Moreover, the absence of the use of 
WTO agreement is another contributing factor behind launching generics of the original brands. 
Chart 3.2.4: Market Share of Top 10 Companies (Year 2011) 
                                                         
 Source: Bangladesh Pharmaceutical Index, 2011 
 
Figure 3.2.4 gives an idea about Market Share of Top 10 Companies in 2011. SQUARE leading 
company of the industry has a remarkable market share gaining history. From 2006 to 2010, its 
market share has increased by 4.14%. Its primary concern like other top local companies is 
generic drugs and new launches. 
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Chart 3.2.5: Top Selling Brands of the Industry (Year 2010) 
 
 
 
 
 
 
 
 
 
Source: Bangladesh Pharmaceutical Index, IMS PLUS 2Q, 2010 (Company Subscribed Software)  
 
Figure 3.2.5 gives an idea about industry‟s top selling brands. It is seen that the top selling brand 
is Seclo which is a product of Square Pharmaceuticals succeeded by Losectil of Eskayef, 
Neotack of Square Pharma, Neoceptin of Beximco Pharma, Pantonix of Incepta Pharma, Napa of 
Beximco Pharma, Cef-3, Ciprocin, Zimax & Lebac of Square Pharmaceuticals Ltd. 
 
However, industry‟s top 10 brands are having more than 50 billion taka sale with 79.82 % 
market share while the rest fall below. Among these 10 brands, about six brands are of Square 
Pharmaceuticals. Therefore, it can be said that maintaining the growth of these brands are crucial 
for Square as a little growth fluctuation of these top brands can lead to serious trouble for the 
company.     
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PART THREE: INTRODUCTION OF Aclasta 
Aclasta
®
 is a prescription medicine used for the treatment of osteoporosis in postmenopausal 
women to reduce the incidence of hip, vertebral and non-vertebral fractures and to increase bone 
mineral density; treatment of osteoporosis in men; treatment of Paget's disease of bone; treatment 
and prevention of glucocorticoid-induced osteoporosis and for the prevention of clinical fractures 
in patients after hip fracture and prevention of postmenopausal osteoporosis. 
Aclasta
®
 is first introduced in Bangladesh by Novartis (Bangladesh) Ltd. in 2008. It was 
invented and produced in Switzerland. It is the first original medicine which contains Zoledronic 
Acid and is known as a revolutionary medical discovery for osteoporosis because of it‟s once a 
year treatment. New bone is formed, replacing old bone to keep the body strong. In case of an 
osteoporosis patient, old bone breaks down faster than new bone can form. Bone loss speeds up around 
the time of menopause. Aclasta is a type of medicine called a bisphosphonate. It works to increase bone 
density because it's an intravenous treatment, Aclasta bypasses the digestive system, going to work to 
help protect from fracture for 12 full months. 
 
Picture 3.3.1 Normal bone matrix and Osteoporosis 
 Year-long Protection  
 One dose helps protect for a year 
With Aclasta
®
, a single yearly intravenous dose, along with daily calcium and vitamin D, 
helps increase bone density, protecting and strengthening the bones. 
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 It goes to work to strengthen bones 
Aclasta
®
 is an intravenous drug. So it bypasses the digestive system, goes directly to 
work to help protect the bones from fracture for a full 12 months. 
 Protects in more places 
Aclasta
®
 is approved to help protect from fracture in hip, spine, and even other bones. 
Here is a brief profile of Aclasta
® 
in Bangladesh: 
 
Type of Brand Global 
Type of Medicine Bisphosphonate 
Market Osteoporosis 
Number of Countries Marketed in 120 
Introduced Year in Bangladesh 2008 
Place of Invention Switzerland 
Place of Production Switzerland 
Form Inject-able 
Major Ingredient Zoledronic Acid 
Maximum Retail Price (BDT) 27,000 
Position in Market Leader 
Position in BCG Matrix Star 
Competing Local Generic Zolenic  
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PORTFOLIO OF ACLASTA 
As mentioned in the previous chapter, Aclasta is enjoying its leading position in the osteoporosis 
market of Bangladesh. As it has a high market share in a growing market like osteoporosis, its 
place in BCG Matrix is on Star.   
Figure 3.2.1: BCG Matrix 
                                               
Features of BCG STAR Aclasta 
 Stars are defined by having high market share in a growing market. As Aclasta
® 
has both 
of them; it can be called a star for Novartis. 
 Stars are the leaders in the business so is Aclasta
®
. 
 Being the market leaders, Stars still need a lot of promotion so is Aclasta
®
. 
 If market share is kept, Stars like Aclasta
® 
are likely to grow into cash cows. 
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PART FOUR: PROBLEM DEFINITION 
3.4.1 Background of the Problem 
Aclasta is used to control osteoporosis (disease of bone loss). Patients were asked to take this 
infusion three times in three months (one time a month). Very recently the doses of infusion have 
been increases which amount to six times in six months on monthly basis. Many patients just 
take the first infusion and do not go for reinfusion. It‟s because either they forget about 
reinfusion or they become dissatisfied after the first infusion. To great extent high pricing of 
Aclasta also becomes the obstacle to refrain patients from taking it. I would like to peruse those 
reasons and the problems pertinent to reinfusion.   
3.4.2 Statement of the Problem 
Here we want to see to the patients who have taken Aclasta reinfusion. We would like to observe 
the variables that actually have driven these patients to go for reinfusion.  We will also oversee 
the reasons which deter the patients from taking reinfusion. The variables we have used here to 
determine the patients‟ satisfaction level are Doctor‟s visit, physical condition after first infusion, 
price of Aclasta, tendency towards substitutes, perceived benefit and many more.  
3.4.3 Decision problem: 
Why patients go for Aclasta reinfusion?  
3.4.4 Research Problem: 
To determine the reasons that drive patients to go for reinfusion. Is it that the patients are 
satisfied with the efficacy of Aclasta or whether the doctors are compelling them to take it so 
they are taking it? 
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APPROACH TO THE PROBLEM 
3.4.5 Research Framework 
Figure 3.4.5: Research Framework of the Study 
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PART FIVE: RESEARCH DESIGN 
3.5.1 Type of Research Design   
For this research, I worked in team of three members. Here we have used both exploratory and 
conclusive research. First we formulated and defined the problem more elaborately and 
identified feasible courses of action. Then we developed the hypotheses which could be the 
potential responses of our sample group and formulated the rest part of research design. Now this 
was followed by the conclusive research which was the single cross-sectional research design, 
and we determined, evaluated and selected an appropriate course of action. 
3.5.2 Information Needed 
There are two kinds of data; primary and secondary data namely. Primary data is originated by 
the data user for the specific purpose of addressing the research problem. Secondary data was 
collected for some other purpose other than the problem on hand and now which is made 
available for the use of all.  
Here we have used both primary and secondary data. Primary data were about the background of 
the sample group of our research respondent: their physical condition after first infusion, doctor 
visit, feelings towards Aclasta, perceived benefit of Aclasta etc. As for secondary data, I 
consulted various online journals, website etc. 
3.5.3 Data Collection 
To elicit the primary data, I have composed the survey result from the company where 120 
patients were asked regarding their approach to reinfusion. In contrast, secondary data are 
collected from the company reports and Novartis featured articles of magazines.  
3.5.4 Questionnaire Development 
A questionnaire with 13 (thirteen) questions are developed for obtaining qualitative as well as 
quantitative primary data in the telephone survey. Some questions are divided into some parts 
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within the questions. In the later part analysis, we have done 17 sub hypotheses under one main 
hypothesis. A sample questionnaire has been attached as Appendix A. 
3.5.5 Methodology 
This study is to some extent Exploratory in nature in association with conclusive nature. Data 
used here is both Qualitative and Quantitative. Most of the data is qualitative. These data are 
collected from both primary and secondary sources. The method of primary data Collection is 
telephone survey and secondary data are collected from company reports, Medical Magazines 
and web-sites. In case of primary research, SPSS software has been used to conduct Chi-Squared 
test, linear regression, paired independent t test etc. 
PART SIX: DATA ANALYSIS 
3.6 Primary data analysis 
Here we majorly will test if the Aclasta reinfusion takers are satisfied with Aclasta drug or they 
take it being complied. Alternatively those who don‟t take Aclasta reinfusion are actually not 
contended with Aclasta. 
Major Hypothesis 
H0:   There is no association between satisfaction of the patients and Aclasta reinfusion 
H1:  There is association between satisfaction of the patients and reinfusion 
 
Chi-Squared Test of Independence of Categorical Variables 
Hypothesis 01 
H0: Impact of feeling well by taking Aclasta and perceived benefit out of Aclasta are 
independent of each other. 
H1: Impact of feeling well influences the perceived benefit out of Aclasta or Perceived benefit 
depends on whether patients feel good or bad. 
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H0 = 0 
H1  0 
H0 states that the variables are independent of each other. 
Here 73 patients suggested that they are feeling well after taking Aclasta and also believe in 
perceived benefit out of Aclasta. The expected frequency for this is 54.4. 11 patients don‟t admit 
the perceived benefit of Aclasta over competitors even though they are feeling well after the 
Aclasta infusion. There are 2 patients who acknowledge the perceived benefit of Aclasta despite 
not feeling well after the infusion.  
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 66.368
a
 3 .000 
Likelihood Ratio 72.279 3 .000 
Linear-by-Linear Association 45.784 1 .000 
N of Valid Cases 120   
a. 3 cells (37.5%) have expected count less than 5. The minimum expected count is 1.10. 
Q1.Feelings after taking Aclasta * q7.Any perceived benefit you have found from Aclasta 
over competitors or substitutes (if you have switching experience)?  
(Cross tabulation) 
 
   Q7.Any perceived benefit have you found from 
Aclasta over competitors or substitutes (if you have 
switching experience)? 
Total    yes no same I don't know 
 
 
q1.Feelings 
after taking 
Aclasta 
Feeling 
well 
Count 73 0 3 11 87 
Expected 
Count 
54.4 2.9 10.9 18.8 87.0 
Not 
feeling 
well 
Count 2 4 12 15 33 
Expected 
Count 
20.6 1.1 4.1 7.2 33.0 
 
Total 
Count 75 4 15 26 120 
Expected 
Count 
75.0 4.0 15.0 26.0 120.0 
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The value of Chi Square statistics is 66.368. The Chi Squared statistic has 3 degrees of freedom. 
Here P value equals .000. Here P value is less than .05. Hence we reject H0. Hence we can 
demonstrate that condition of feeling well influences or reinforces the perceived benefit out of 
Aclasta. 
Hypothesis 02: 
H0:  Choice of taking reinfusion is independent of willingness to attend Aclasta Patient Meeting. 
H1: Choice of taking reinfusion leads patients to attend the Aclasta Patient Meeting.  
 
q2. I am taking Reinfusion * q5.Are you interested to attend Aclasta Patient Meeting?  
(Cross tabulation) 
 
   Q5.Are you interested to attend coming 
Aclasta Patient Meeting? 
Total    yes no may be 
 
 
 
 
 
       q2. 
I am taking 
Reinfusion 
Because I am happy 
with first Infusion 
Count 24 11 5 40 
Expected 
Count 
17.3 13.3 9.3 40.0 
Because doctor has 
prescribed 
Count 13 4 7 24 
Expected 
Count 
10.4 8.0 5.6 24.0 
Because of not much 
improvement of  
health I have gone 
for re-infusion 
Count 1 8 6 15 
Expected 
Count 6.5 5.0 3.5 15.0 
Haven't gone for re-
infusion 
Count 14 17 10 41 
Expected 
Count 
17.8 13.7 9.6 41.0 
Total Count 52 40 28 120 
Expected 
Count 
52.0 40.0 28.0 120.0 
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Here we can see that 24 patients are attending the Aclasta Patient Meeting as they are happy with 
the first Aclasta Infusion. 11 patients revealed that even though they are happy with the first 
infusion but they are not attending in the upcoming meeting. We can also see that 14 patients 
have not yet decided to go for reinfusion, still they are attending Patient meeting. 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 17.855
a
 6 .007 
Likelihood Ratio 20.407 6 .002 
Linear-by-Linear Association 6.190 1 .013 
N of Valid Cases 120   
a. 1 cells (8.3%) have expected count less than 5. The minimum expected count is 3.50. 
 
The value of Chi Square Statistics is 17.855 containing 6 degrees of freedom. P value is .007 
which is less than .05. Thus we can reject H0. We can state that Choice of reinfusion influences 
patients‟ desire to attend Aclasta Patient Meeting. 
 
 
Hypothesis 03: 
 
H0: The choice of being loyal or not with Aclasta and thoughts about discounting process are 
independent of each other. 
H1: Choice of being loyal or not with Aclasta and thoughts about discounting process are not 
independent of each other. 
That is the choice of whether to be loyal to Aclasta depends on whether you like the discounting 
procedure of Aclasta. 
 
H0 = 0 
H1  0 
 
H0 states that the variables are independent of each other. 
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q9c. Discounting process/ procedure * q13.I have switched to another doctor, but still 
continuing with Aclasta reinfusion  
Cross tabulation 
   q13.I have switched to 
another doctor, but still 
continuing with Aclasta 
reinfusion 
Total    True False 
 
 
 
 
q9c. 
Discounting 
process/ procedure 
Excellent Count 4 1 5 
Expected Count 1.9 3.1 5.0 
Good Count 20 18 38 
Expected Count 14.6 23.4 38.0 
Neutral Count 19 29 48 
Expected Count 18.4 29.6 48.0 
bad Count 3 23 26 
Expected Count 10.0 16.0 26.0 
Very bad Count 0 3 3 
Expected Count 1.2 1.8 3.0 
Total Count 46 74 120 
Expected Count 46.0 74.0 120.0 
 
 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
q9c. Discounting process/ 
procedure * q13.I have 
switched to another doctor, 
but still continuing with 
Aclasta reinfusion 
120 100.0% 0 .0% 120 100.0% 
Case Processing Summary 
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Here we see that 4 patients who think discounting process of Aclasta is excellent also are loyal 
towards it despite switching a doctor. We also find here 1 patient won‟t be loyal even if he/she 
thinks that discounting process is excellent.  19 patients would be loyal to Aclasta although they 
think discounting procedure is not that good (neutral). The expected frequency for this cell under 
H0 is 18.4. 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 16.752
a
 4 .002 
Likelihood Ratio 19.143 4 .001 
Linear-by-Linear Association 15.908 1 .000 
N of Valid Cases 120   
a. 4 cells (40.0%) have expected count less than 5. The minimum expected count is 1.15. 
The value of Chi-Squared statistic is 16.752. Here P value associated with Chi-square is .002. 
Here P value being less than .05, we can reject H0. Hence patients who are happy with 
discounting process of Aclasta tend to be loyal towards it. 
 
 
Mann Whitney U Test 
Now we want to test that people who think high pricing of Aclasta is justified also feel Aclasta is 
the most effective drug for osteoporosis. 
 
Hypothesis 04: 
 
H0: µPricing  µNoPricing 
H1: µPricing< µNoPricing 
 
The mean responses of the patients regarding „High pricing is justified for Aclasta‟ is 1.88 
(among agree, undecided and disagree) and the mean response for the reply of whether „Aclasta 
is the most effective drug‟ is 1.48 (among agree, undecided and don‟t agree). 
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Mann-Whitney 
Ranks 
Q8d.High pricing is justified for 
Aclasta as it‟s brought from Abroad. 
N 
Mean 
Rank 
Sum of Ranks 
q8a.Aclasta is the most 
effective drug for 
osteoporosis 
agree 47 28.67 1347.50 
don't agree 33 57.35 1892.50 
Total: 80   
47 patients agreed with the fact that „aclasata‟s high pricing is justified‟. 33 patients don‟t agree 
with the high pricing of Aclasta.  
 
 
Test Statistics 
 
q8a.Aclasta is the most effective drug for osteoporosis 
Mann-Whitney U 219.500 
Wilcoxon W 1347.500 
Z -6.430 
Asymp. Sig. (2-tailed) 
.000 
a. Grouping Variable: q8d.High pricing is justified as Aclasta is brought from abroad and its 
effectiveness is quite high unless patents have other major health diseases 
Descriptive statistics 
 
 N Mean Std. Deviation Minimum Maximum 
q8a.Aclasta is the most 
effective drug for 
osteoporosis 
120 1.48 .698 1 3 
q8d.High pricing is justified 
as Aclasta is brought from 
abroad and its effectiveness 
is quite high unless patents 
have other major health 
diseases 
120 1.88 .812 1 3 
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The final section of the output gives the values of the Mann-Whitney U test (and several other 
tests as well.) The observed Mann-Whitney U value is given at the intersection of the row 
labeled Mann-Whitney U and the column labeled with the dependent variable (Aclasta is the 
most effective drug). Here Mann Whitney U value is 219.500. P value is given -- one on the row 
labeled Asymp Sig (2-Tailed). It is a two-tailed p value, but we have a one-tailed test. So we 
need to divide the two-tailed p value by 2 to get the one-tailed p value: here it is .000 which is 
less than .05. Hence we reject null hypothesis.  
So patients who think high pricing of Aclasta is justified also feel it‟s the most effective drug. 
 
Hypothesis 05: 
 
H0: µRecall  µNoRecall 
H1: µRecall< µNoRecall 
 
Now we want to test that patients who can recall their reinfusion date, are also happy with the 
discounting process of Aclasta. 
 
Descriptive Statistics 
 
N Mean Std. Deviation Minimum Maximum 
q9c. Discounting process/ 
procedure 
120 2.87 .888 1 5 
Q10.Do you remember your 
reinfusion date? 
120 1.50 .502 1 2 
 
The mean response of discounting process is 2.87 (between excellent and very bad). More 
patients want additional discount than existing discount value and mean responses of „who 
remember their reinfusion date‟ is .502.  
From 120 patients, 60 patients remember their reinfusion date and another 60 patients don‟t 
remember their reinfusion date. Those who remember reinfusion date , their perceived mean rank 
of discounting procedure of Aclasta is 51.19 and those who don‟t remember their reinfusion date 
their perceived mean rank of Aclasta‟s  discounting procedure is 69.81. 
 
  46 
Mann-Whitney Test 
 
Ranks 
Q10.Do you remember your reinfusion 
date? N Mean Rank Sum of Ranks 
 
q9c. Discounting process/ 
procedure 
yes 60 51.19 3071.50 
no 60 69.81 4188.50 
Total 120   
 
 
                       Test Statistics 
 
q9c. Discounting process/ procedure 
Mann-Whitney U 1241.500 
Wilcoxon W 3071.500 
Z -3.100 
Asymp. Sig. (2-tailed) .002 
a. Grouping Variable: q10.Do you remember your reinfusion date? 
Here Mann Whitney U value is 1241.500. P value is given on the row labeled as Asymp. Sig (2-
Tailed). It is a two-tailed p value, but we have a one-tailed test. So we need to divide the two-
tailed p value by 2 to get the one-tailed p value: here it is .002 which is already less than .05. 
Hence we reject null hypothesis.  
Thus we can manifest that patients who tend to remember their reinfusion date are happy with 
the discounting process of Aclasta. 
 
One way Anova of variances 
Here we will test if the doctor‟s visit influences the continuation of Aclasta reinfusion. 
Here, 
Hypothesis 06: 
 
H0: µLess than 500 = µ500 = µmore than 500    
H1: not H0 
µ represents mean possibility of taking Aclasta reinfusion. 
  47 
 
Here 25 patients who pay doctor‟s visit less than 500 BDT have the mean value of taking 
reinfusion is 1.40 (Between yes=1 and no=2). 49 patients pay more than 500 BDT and have 
mean possibility of continuing Aclasta of 1.38.  
 
Test of Homogeneity of Variances 
q4.Will you take reinfusion 
  
Levene Statistic df1 df2 Sig. 
1.712 2 117 .185 
 
The Test of Homogeneity of Variances output tests H0: σ
2
less than 500 = σ
2
500 = σ
2
more than 500 
 
Here, P value is .185 which is greater than .05. We fail to reject H0 implying that there is little 
evidence that the variances are not equal and the homogeneity of variance assumption may be 
reasonably satisfied.  
 
 
 
Descriptive 
        
q4.Will 
you take 
reinfusio
n 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence Interval 
for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
Less 
than 500 
25 1.40 .500 .100 1.19 1.61 1 2 
500 46 1.41 .498 .073 1.27 1.56 1 2 
more 
than 500 
49 1.33 .474 .068 1.19 1.46 1 2 
Total 120 1.38 .486 .044 1.29 1.46 1 2 
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ANOVA 
q4.Will you take reinfusion     
 Sum of Squares df Mean Square F Sig. 
Between Groups 
.197 2 .099 .413 .662 
Within Groups 27.928 117 .239   
 
Total 
 
28.125 
 
119 
   
 
We would write the F ratio as: The one-way, between-subjects analysis of variance failed to 
reveal a reliable effect of Doctor‟s visit on Continuation of reinfusion, F(2, 117) = 0.413, p = 
.662, MSerror = 0.239, α = .05. 
The 2 is the between-groups degrees of freedom, 117 is the within-groups degrees of freedom, 
0.413 is the F ratio from the F column, .662 is the value in the Sig. column (the p value), and 
0.239 is the within-groups mean square estimate of variance. Here we fail to reject H0. F ratio is 
statistically significant. 
Let‟s look at multiple comparisons: 
Post Hoc Tests 
 
Here, the mean difference between the Reinfusion continuation of the patients paying less than 
500 BDT and patients paying 500 BDT and more than 500 BDT is consecutively -.013 and .073. 
The p value for comparing the possibility of Reinfusion continuation of people who pay less than 
500 BDT with those who would be paying 500 BDT is 0.994, meaning that it is unlikely that 
these means are different. So we still can‟t reject null hypothesis. Here all the comparison P 
value (Sig.) is significantly more than .05. We can signify mean possibility of the patients for 
reinfusion is same regardless of Doctor‟s visit. 
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Multiple Comparisons 
q4. Will you take reinfusion 
 
(I) Doctor's 
visit 
(J) Doctor's 
visit 
Mean 
Difference  
(I-J) 
Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Less than 500 500 -.013 .121 .994 -.30 .28 
more than 500 .073 .120 .814 -.21 .36 
500 Less than 500 .013 .121 .994 -.28 .30 
more than 500 .087 .100 .665 -.15 .32 
more than 500 Less than 500 -.073 .120 .814 -.36 .21 
500 -.087 .100 .665 -.32 .15 
 
 
q4.Will you take reinfusion 
Tukey HSD   
Doctor's visit N 
Subset for alpha = 0.05 
1 
more than 500 49 1.33 
Less than 500 25 1.40 
500 46 1.41 
Sig.  .730 
Means for groups in homogeneous subsets are displayed. 
The means listed in each subset column are not statistically reliably different from each other. In 
this example, all four means are listed in a single subset column, so none of the means are 
reliably different from any of the other means. That is not to say that the means are not different 
from each other, but only that we failed to observe a difference between any of the means. This 
is consistent with the fact that we failed to reject the null hypothesis of the ANOVA. 
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Linear Regression 
 
Descriptive Statistics 
 
Mean Std. Deviation N 
q9b.Awareness of Aclasta 
1.88 .795 120 
q9a.Availability of stores 
2.26 .903 120 
 
Here correlation between Awareness and itself is 1 and correlation between availability of stores 
and itself is 1.  
Correlations 
  q9b.Awareness of 
Aclasta 
q9a.Availability of 
stores 
Pearson Correlation 
q9b.Awareness of 
Aclasta 
1.000 .678 
q9a.Availability of stores .678 1.000 
Sig. (1-tailed) 
q9b.Awareness of 
Aclasta 
- .000 
q9a.Availability of stores .000 - 
N 
q9b.Awareness of 
Aclasta 
120 120 
q9a.Availability of stores 120 120 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .678
a
 .460 .455 .587 
a. Predictors: (Constant), q9a.Availability of stores 
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ANOVA 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 34.534 1 34.534 100.392 .000
a
 
Residual 40.591 118 .344   
Total 75.125 119    
a. Predictors: (Constant), q9a.Availability of stores   
b. Dependent Variable: q9b.Awareness of Aclasta   
 
 
Predicted value of "availability of stores" = .597 X value of awareness of Aclasta + .527. If we 
take the score 2 from the questionnaire of availability of stores it turns out 1.721, positive result. 
Hence patients who think availability of the Aclasta stores are excellent also think awareness 
campaign of Aclasta is excellent. 
Paired Samples t-Tests 
Hypothesis 07: 
H0: µabstinence from Aclasta due to dissatisfaction with doctor = µignoring doctor‟s advice to go for 
reinfusion 
H1: µ abstinence from Aclasta due to dissatisfaction with doctor≠ µignoring doctor‟s advice to go for 
reinfusion 
µ is the mean number of responses of patients. 
Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
B Std. Error Beta 
1 (Constant) .527 .145  3.644 .000 
q9a.Availability of 
stores 
.597 .060 .678 10.020 .000 
a. Dependent Variable: q9b.Awareness of Aclasta    
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This gives the descriptive statistics for each of the two groups (as defined by the pair of 
variables.) In this example, there are 120 people who responded to the Dissatisfaction with 
Doctor Question (N), and they have, on average, 1.58 (among agree=1, and don‟t agree=2), with 
a standard deviation of .496. These same 120 people also responded to the „Ignoring doctor‟s 
prescription‟ question (N), and they have, on average, 1.73(between true and false), with a 
standard deviation of .448. The last column gives the standard error of the mean for each of the 
two variables. 
 
  
N Correlation Sig. 
Mean Std.error 
mean 
SD 
Pair 1 
q11. I don't take Aclasta 
infusion/reinfusion as I am 
dissatisfied with my doctor & 
q12.Being aware of Aclasta 
reinfusion I would/have gone for 
reinfusion ignoring my doctor's 
prescription 
120 .000 .992 -.150 .061 .669 
 
 
Paired Samples Statistics 
  
Mean N Std. Deviation Std. Error Mean 
 
 
 
 
  Pair 1 
q11. I don't take Aclasta 
infusion/reinfusion as I am 
dissatisfied with my doctor 
1.58 120 .496 .045 
q12.Being aware of Aclasta 
reinfusion I would/have 
gone for reinfusion 
ignoring my doctor's 
prescription 
1.73 120 .448 .041 
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Here r= .000 and the p value is .992 which is more than Alpha. So we fail to reject the null 
hypothesis. That is, there is insufficient evidence to conclude that the population correlation (ρ) 
is different from 0. 
Below the difference of the 2 means and std. deviation is consecutively -.150 and .669. T value is 
-2.455. P value is .016. Here P value is less than Alpha hence we can reject the null hypothesis. 
We imply that there is sufficient evidence to conclude that the kind of responses to whether to 
abstain from reinfusion being dissatisfied with doctor and whether to take reinfusion ignoring 
doctor is different. 
Independent Samples t-Tests Single Value Groups 
 
We will test here if the male and female pays doctor‟s visit in different proportions. 
 
Hypothesis 08: 
H0: µmale = µfemale 
H1: µmale 1 ≠ µfemale 
where µ is the mean amount of doctors‟ visits. 
 
 
Group Statistics 
 
Gender N Mean Std. Deviation Std. Error Mean 
Doctor's visit 
male 45 2.13 .786 .117 
female 75 2.24 .750 .087 
 
Here 45 male patients pay the mean of 2.13 for doctor‟s visit. And 75 female patients pay mean 
of 2.24 for doctor‟s visit.  
 
Here is a column labeled "Sig." under the heading "Levene's Test for Equality of Variances". In 
this test, the significance (p value) of Levene's test is .932. Here the P value is more than alpha. 
So we assume that the variances are equal. Calculated t value is .740 (negative sign can be 
omitted here). 2 tailed p value associated with this test is .461. We fail to reject H0. That implies 
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that we failed to observe a difference in the amount of doctor visits between the male and female 
patients. 
 
 
 
 
  Levene's Test 
for Equality 
of Variances 
t-test for Equality of Means 
  
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
  Lower Upper 
Doctor's 
visit 
Equal 
variances 
assumed 
.007 .932 -.740 118 .461 -.107 .144 -.392 .179 
Equal 
variances 
not 
assumed 
  
-.732 89.375 .466 -.107 .146 -.396 .183 
 
Chi-Squared test 
 
Hypothesis 09: 
 
H0: the reasons of taking reinfusion and choice of whether to take it are independent of each 
other. 
H1: The reasons of taking reinfusion and choice of whether to take it are not independent. That is 
the reasons of taking reinfusion influences the decision of taking it. 
 
 
 
 
Independent Sample t test 
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Here patients who are happy with first Aclasta infusion, among them 90% are going for 
reinfusion. And those who are going for reinfusion, among them 48% are happy with the first 
q2.I am taking Reinfusion * q4.Will you take reinfusion (Cross tabulation) 
   q4.Will you take 
reinfusion 
Total    yes no 
q2. 
I am taking 
Reinfusion 
Because I am 
happy with first 
Infusion 
Count 36 4 40 
% within q2.I am taking Reinfusion 90.0% 10.0% 100.0% 
% within q4.Will you take reinfusion 48.0% 8.9% 33.3% 
% of Total 30.0% 3.3% 33.3% 
Because doctor 
has prescribed 
Count 18 6 24 
% within q2.I am taking Reinfusion 75.0% 25.0% 100.0% 
% within q4.Will you take reinfusion 24.0% 13.3% 20.0% 
% of Total 15.0% 5.0% 20.0% 
Because of not 
much 
improvement of 
health I have 
gone for re-
infusion 
Count 6 9 15 
% within q2.I am taking Reinfusion 40.0% 60.0% 100.0% 
% within q4.Will you take reinfusion 
8.0% 20.0% 12.5% 
% of Total 
5.0% 7.5% 12.5% 
Haven't gone 
for re-infusion 
Count 15 26 41 
% within q2.I am taking Reinfusion 36.6% 63.4% 100.0% 
% within q4.Will you take reinfusion 20.0% 57.8% 34.2% 
% of Total 12.5% 21.7% 34.2% 
Total 
Count 75 45 120 
% within q2.I am taking Reinfusion 62.5% 37.5% 100.0% 
% within q4.Will you take reinfusion 100.0% 100.0% 100.0% 
% of Total 62.5% 37.5% 100.0% 
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infusion. On total from both „reinfusion taker ns non taker‟ category 33.3% have ticked they are 
happy with first infusion and overall Aclasta infusion.  
Within „I am going for reinfusion‟ group 75% of the patients mention that they abide by their 
doctor‟s prescriptions. And on total 20% of the patients have ticked the option „As doctor has 
prescribed‟. On total 62% patients who said that they will take reinfusion. Patients who haven‟t 
come across much improvement after first infusion, among them 40% are taking reinfusion. 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 29.495
a
 3 .000 
Likelihood Ratio 31.736 3 .000 
Linear-by-Linear Association 27.979 1 .000 
N of Valid Cases 120   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.63. 
When readings this table we are interested in the results for the Continuity correction. We can 
see here that Chi-square (3) = 29.495, P = 0.000. Hence reasons of taking Aclasta reinfusion 
strongly affect the decision of taking it. So we reject the null hypothesis. 
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Hypothesis 10: 
H0: Compliance with high pricing and choice of whether to take it are independent of each other. 
H1: Compliance with high pricing and choice of whether to take it are not independent. That is 
positive or negative compliance with pricing influences the decision of taking it. 
 
q8d.High pricing is justified as Aclasta is brought from abroad and its effectiveness is quite high 
unless patents have other major health diseases * q4.Will you take reinfusion  
(Cross tabulation) 
   q4.Will you take 
reinfusion 
Total    yes no 
q8d.High pricing 
is justified as 
Aclasta is brought 
from abroad and 
its effectiveness is 
quite high unless 
patients have other 
major health 
diseases 
agree Count 34 13 47 
% within q8d.High pricing is justified for 
Aclasta  
72.3% 27.7% 
100.0
% 
% within q4.Will you take reinfusion 45.3% 28.9% 39.2% 
% of Total 28.3% 10.8% 39.2% 
undecided Count 25 15 40 
% within q8d.High pricing is justified for  
62.5% 37.5% 
100.0
% 
% within q4.Will you take reinfusion 33.3% 33.3% 33.3% 
% of Total 20.8% 12.5% 33.3% 
don't agree Count 16 17 33 
% within q8d.High pricing is justified for 
Aclasta  
48.5% 51.5% 
100.0
% 
% within q4.Will you take reinfusion 21.3% 37.8% 27.5% 
% of Total 13.3% 14.2% 27.5% 
Total 
Count 75 45 120 
% within q8d.High pricing is justified for 
Aclasta  
62.5% 37.5% 
100.0
% 
% within q4.Will you take reinfusion 
100.0% 100.0% 
100.0
% 
% of Total 
62.5% 37.5% 
100.0
% 
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Here 73.2% of patients within „high pricing: agree‟ category will take reinfusion. And who will 
take reinfusion: among them 45.3% agree that the high pricing of Aclasta is justified. In total 
62.5% patients in „Pricing category‟ question have decided to take reinfusion. Those who don‟t 
comply with the pricing of Aclasta, 48.5% of them are taking reinfusion. 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.708
a
 2 .095 
Likelihood Ratio 4.700 2 .095 
Linear-by-Linear Association 4.620 1 .032 
N of Valid Cases 120   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 12.38. 
Here Chi-square statistic is 4.708. P= .095 which is more than .05. That means we can‟t reject 
null hypothesis. Thus we can state that agreeable or negative compliance with the high pricing of 
Aclasta has no effect on the decision of the patients regarding reinfusion. 
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Sign Test and Wilcoxon Matched-Pairs Signed-Rank Test 
 
Hypothesis 11: 
H0: µmoney= µdiscount 
H1: µmoney  µdiscount 
 
Descriptive Statistics 
 
N Mean Std. Deviation Minimum Maximum 
q8b.Money doesn't matter as 
long as the health is 
concerned 
120 1.38 .674 1 3 
q8c. Discount prompts us to 
buy Aclasta 
120 1.32 .622 1 3 
 
Here mean compliance rating of the patients to whom „money doesn‟t matter as long as the 
Aclasta is effective‟ is 1.38. Mean compliance ranking of the patients to whom discount prompts 
them to buy Aclasta is 1.32.  
 
Wilcoxon Signed Ranks Test 
 
Ranks 
  N Mean Rank Sum of Ranks 
q8c. Discount prompts 
us to buy Aclasta - 
q8b.Money doesn't 
matter as long as the 
health is concerned 
Negative Ranks 22
a
 20.20 444.50 
Positive Ranks 17
b
 19.74 335.50 
Ties 81
c
   
Total 120   
a. q8c. Discount prompts us to buy Aclasta < q8b.Money doesn't matter as long as the health is 
concerned 
b. q8c. Discount prompts us to buy Aclasta > q8b.Money doesn't matter as long as the health is 
concerned 
c. q8c. Discount prompts us to buy Aclasta = q8b.Money doesn't matter as long as the health is 
concerned 
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Patients‟ compliance with discount has the less compliance likeability than the patients‟ 
compliance likeability with the money fact where observations amount to 22. It also gives the 
number of observations= 17 where patients pursuing discount have more compliance likeability 
than the patients who pursue healing in cost of any amount of money. 81 observations convey 
the same compliance rating in both category/group. 
 
Test Statistics 
 
q8c. Discount prompts us to buy Aclasta - 
q8b.Money doesn't matter as long as the 
health is concerned 
Z -.796
a
 
Asymp. Sig. (2-tailed) .426 
a. Based on positive ranks. 
b. Wilcoxon Signed Ranks Test 
 
The P value associated with Wilcoxon test is .426.  
Frequencies 
  N 
q8c. Discount prompts 
us to buy Aclasta - 
q8b.Money doesn't 
matter as long as the 
health is concerned 
Negative 
Differences 
22 
Positive Differences 17 
Ties
c
 81 
Total 120 
a. q8c. Discount prompts us to buy Aclasta < q8b.Money doesn't matter as long as the health is 
concerned 
b. q8c. Discount prompts us to buy Aclasta > q8b.Money doesn't matter as long as the health is 
concerned 
c. q8c. Discount prompts us to buy Aclasta = q8b.Money doesn't matter as long as the health is 
concerned 
 
The output gives same outcome as in Wilcoxon test.  
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Test Statistics 
q8c. Discount prompts us to buy Aclasta - q8b.Money doesn't matter as long as the health is 
concerned 
Z -.641 
Asymp. Sig. (2-tailed) .522 
a. Sign Test  
 
The final section of the output gives the values of the Sign test. The P value associated with Sign 
test and Wilcoxon test is consecutively .522 and .426. We can‟t reject null hypothesis as mean 
compliance rating for „discount‟ and „money justification for Health‟ is not same. 
Hypothesis 12: 
H0: µrecalling= µreinfusion decision  
H1: µrecalling  µreinfusion decision 
Descriptive Statistics 
 
N Mean 
Std. 
Deviation Minimum Maximum 
q4.Will you take 
reinfusion 
120 1.38 .486 1 2 
q10.Do you remember 
your reinfusion date? 
120 1.50 .502 1 2 
 
Here we want to compare the mean acceptance rate of „patients who will take reinfusion‟ with 
„who remember their reinfusion date‟. Here we can see that patients going to take Aclasta 
reinfusion imply mean acceptance rank of 1.38. And patients who remember their reinfusion 
date, their mean acceptance rank are 1.50. 
P value associated with Wicoxon test is .001. Here we see 10 observations- where recall ability 
rank of reinfusion is less than reinfusion acceptance liability. And among 25 observations 
Remember ability overweighs the reinfusion acceptance rank. Among 85 observations remember 
ability and reinfusion acceptance rate/rank is same. 
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Test Statistics
b
 
 
Q10.Do you remember your reinfusion date? 
- q4.Will you take reinfusion 
Z -2.535
a
 
Asymp. Sig. (2-tailed) .011 
a. Based on negative ranks. 
b. Wilcoxon Signed Ranks Test 
Sign 
 
Frequencies 
  N 
q10.Do you remember 
your reinfusion date? 
 –  
 
q4.Will you take 
reinfusion 
Negative 
Differences
a
 
10 
Positive 
Differences
b
 
25 
Ties
c
 85 
Total 120 
a. q10.Do you remember your reinfusion date? < q4.Will you take reinfusion 
b. q10.Do you remember your reinfusion date? > q4.Will you take reinfusion 
c. q10.Do you remember your reinfusion date? = q4.Will you take reinfusion 
 
 
 
Ranks 
  N Mean Rank Sum of Ranks 
Q10.Do you remember 
your reinfusion date? - 
q4.Will you take 
reinfusion 
Negative Ranks 10
a
 18.00 180.00 
Positive Ranks 25
b
 18.00 450.00 
Ties 85
c
   
Total 120   
a. q10.Do you remember your reinfusion date? < q4.Will you take reinfusion 
b. q10.Do you remember your reinfusion date? > q4.Will you take reinfusion 
c. q10.Do you remember your reinfusion date? = q4.Will you take reinfusion 
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Test Statistics 
 
q10. Do you remember your reinfusion 
date? - q4.Will you take reinfusion 
Z -2.366 
Asymp. Sig. (2-tailed) .018 
a. Sign Test  
 
In both Wilcoxon and Sign test P value is less than .05. Hence we reject null hypothesis. Hence 
mean recall ability rank is same as mean reinfusion acceptance rank. 
 
Chi-Squared Test of Independence of Categorical Variables 
Hypothesis 13: 
H0:  Continuation with Aclasta in spite of switching doctor and response to effectiveness of 
Aclasta are independent. 
H1: Continuation with Aclasta depends on the kind of response to effectiveness of Aclasta. 
 
Case Processing Summary 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
q8a.Aclasta is the most 
effective drug for 
osteoporosis * q13.I have 
switched to another doctor, 
but still continuing with 
Aclasta reinfusion 
120 100.0% 0 .0% 120 100.0% 
 
 
Here we can demonstrate that 41 patients agreed that Aclasta is the most effective drug and they 
will be loyal to Aclasta even after changing doctor.35 patients wont undertake the risk of 
continuing Aclasta after switching doctor, although they believe with the utmost effectiveness of 
Aclasta.  
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Value of the Chi-squared statistic is 22.499. We reject null hypothesis as P value is less than .05. 
We can apprise that patients who believe in efficacy of Aclasta also tend to show loyalty toward 
Aclasta.  
 
q8a.Aclasta is the most effective drug for osteoporosis * q13.I have switched to another 
doctor, but still continuing with Aclasta reinfusion  
Cross tabulation 
   q13.I have switched to another 
doctor, but still continuing 
with Aclasta reinfusion 
Total    True False 
q8a.Aclasta is the most 
effective drug for 
osteoporosis 
agree Count 41 35 76 
Expected Count 29.1 46.9 76.0 
undecided Count 5 25 30 
Expected Count 11.5 18.5 30.0 
don't agree Count 0 14 14 
Expected Count 5.4 8.6 14.0 
Total Count 46 74 120 
Expected Count 46.0 74.0 120.0 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 22.499
a
 2 .000 
Likelihood Ratio 27.844 2 .000 
Linear-by-Linear Association 21.493 1 .000 
N of Valid Cases 120   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.37. 
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Linear Regression 
Descriptive Statistics 
 
Mean Std. Deviation N 
q4.Will you take reinfusion 
1.38 .486 120 
q1.Feelings after taking Aclasta 
1.28 .448 120 
 
Reponses of the question „will you take reinfusion‟ has a mean response of 1.38 (yes=1, n=2) 
and responses of „feelings after taking Aclasta‟ has mean response of 1.28(1=feeling well, 2=not 
feeling well 
 
Correlations 
  
q4.Will you take 
reinfusion 
q1.Feelings after 
taking Aclasta 
Pearson Correlation q4.Will you take reinfusion 1.000 .448 
q1.Feelings after taking 
Aclasta 
.448 1.000 
Sig. (1-tailed) q4.Will you take reinfusion 
. .000 
q1.Feelings after taking 
Aclasta 
.000 . 
N q4.Will you take reinfusion 
120 120 
q1.Feelings after taking 
Aclasta 
120 120 
 
 
 
 
 
 
  66 
Variables Entered/Removed 
Model Variables Entered Variables Removed Method 
1 q1.Feelings after taking Aclasta
a
 . Enter 
a. All requested variables entered.  
b. Dependent Variable: q4.Will you take reinfusion 
 
Model Summary 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .448
a
 .201 .194 .436 
a. Predictors: (Constant), q1.Feelings after taking Aclasta 
20% of dependent variance is explained by the collection of independent variables. 
 
 
ANOVA 
Model 
Sum of 
Squares df Mean Square F Sig. 
1 Regression 5.649 1 5.649 29.654 .000
a
 
Residual 22.476 118 .190   
Total 28.125 119    
a. Predictors: (Constant), q1.Feelings after taking Aclasta 
b. Dependent Variable: q4.Will you take reinfusion 
 
 
Hypothesis 14:  
H0: Feeling after taking Aclasta has no impact on decision taking reinfusion 
H1: Feeling after taking Aclasta has significant impact on decision of taking Aclasta. 
The effect of „feelings after Aclasta‟ (B= .486, P= .000) is significant and its coefficient is 
positive. So the greater positive the feeling is, the greater the possibility of going for reinfusion. 
Hence patients feeling well after taking Aclasta will intend to take reinfusion. If the patients are 
feeling well after taking Aclasta then they have the high chance of going for reinfusion. 
Considering the P value we find that the value is lower than .05. So we reject null hypothesis 
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implying that patients‟ health condition after taking Aclasta has significant effect on decision of 
taking reinfusion.  
 
Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) .755 .121  6.268 .000 
q1.Feelings after taking 
Aclasta 
.486 .089 .448 5.446 .000 
a. Dependent Variable: q4.Will you take reinfusion    
 
Chi-squared test 
Hypothesis 15: 
H0: There is no association between the responses to the question „reasons for abstinence from 
reinfusion‟ and decision of taking reinfusion. 
H1: there is association between the responses to „reasons for abstinence‟ and „decision on taking 
reinfusion‟. 
 
Case Processing Summary 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
q3.I won‟t go for re-infusion  
* q4.Will you take reinfusion 120 100.0% 0 .0% 120 100.0% 
 
Those who chose that their probable abstinence from taking reinfusion would be high price, 
76.4% of them are going for reinfusion. Those who have cured after the first infusion, among 
them 52% of patients are not taking reinfusion. Patients, who would only stop reinfusion if 
doctor suggests among them 66.7% of patients are taking reinfusion. On total 62.5% of patients 
is taking reinfusion. Fear of the side effects doesn‟t deter patients from taking reinfusion. 
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q3.I won’t go for re-infusion  * q4.Will you take reinfusion Crosstabulation 
   q4.Will you take 
reinfusion 
Total    yes no 
q3.I won‟t go for 
re-infusion  
Because price is so high 
that even after being 
satisfied can‟t take 
Count 16 5 21 
% within q3.I won‟t go 
for re-infusion  
76.2% 23.8% 100.0% 
I am feeling well, hence 
don't feel the necessity 
to take it 
Count 12 13 25 
% within q3.I won‟t go 
for re-infusion  
48.0% 52.0% 100.0% 
Doctor has not 
prescribed 
Count 16 8 24 
% within q3.I won‟t go 
for re-infusion  
66.7% 33.3% 100.0% 
I have switched to 
another substitute 
Count 1 6 7 
% within q3.I won‟t go 
for re-infusion  
14.3% 85.7% 100.0% 
I am dissatisfied after 
taking first Infusion 
Count 0 10 10 
% within q3.I won‟t go 
for re-infusion  
.0% 100.0% 100.0% 
forgot about the 
reinfusion date 
Count 16 3 19 
% within q3.I won‟t go 
for re-infusion  
84.2% 15.8% 100.0% 
scared of the side effects Count 14 0 14 
% within q3.I won‟t go 
for re-infusion  
100.0% .0% 100.0% 
Total Count 75 45 120 
% within q3.I won‟t go 
for re-infusion  
62.5% 37.5% 100.0% 
 
Here we see that P value is less than .05. Hence we can reject null hypothesis denoting that there 
is an association between the responses to „reason for being abstinent from reinfusion‟ and 
„decision of whether to take reinfusion‟. 
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Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 39.930
a
 6 .000 
Likelihood Ratio 48.237 6 .000 
Linear-by-Linear Association 
1.974 1 .160 
N of Valid Cases 120   
a. 3 cells (21.4%) have expected count less than 5. The minimum expected count is 2.63. 
 
 
 
Hypothesis 16: 
 
H0: People will not take reinfusion just because doctor has prescribed,    µ = 2 
H1: People will take reinfusion because doctor prescribed, µ ≠ 2            
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Statistics 
q2.I am taking Reinfusion 
N Valid 120 
Missing 0 
Mean 2.48 
Median 2.00 
Mode 4 
Std. Deviation 1.270 
Minimum 1 
Maximum 4 
 
 
 
 
q2. I am taking Reinfusion 
  
Frequency Percent Valid Percent 
Cumulativ
e Percent 
 
 
 
 
Valid 
Because I am happy with first 
Infusion 
40 33.3 33.3 33.3 
Because doctor has 
prescribed 
24 20.0 20.0 53.3 
Because of not much 
improvement of health I have 
gone for re 
15 12.5 12.5 65.8 
Haven't gone for re 41 34.2 34.2 100.0 
Total 120 100.0 100.0  
 
 
 
 
 
Frequency 
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One-Sample Statistics 
 
N Mean Std. Deviation Std. Error Mean 
q2.I am taking Reinfusion 
120 2.48 1.270 .116 
 
 
One-Sample Test 
 Test Value = 2                                        
 
t df 
Sig. (2-
tailed) 
Mean 
Difference 
95% Confidence Interval 
of the Difference 
 Lower Upper 
q2.I am taking 
Reinfusion 
4.097 119 .000 .475 .25 .70 
 
So we can reject null hypothesis and adduce that patients tend to take reinfusion because of 
doctors‟ prescription. 
Hypothesis 17: 
H0: Response to Availability of stores has no impact on reinfusion decision  
H1: Response to availability of stores has impact on decision of reinfusion because doctor 
prescribed,            
Patients who ticked on „Excellent‟ option regarding Availability of Aclasta stores, among them 
62.5% of the patients have decided to go for reinfusion. 37.5% of patients are not taking 
reinfusion even though think availability of Aclasta stores is excellent. Patients who think 
availability of stores is good among them 79.6% of patients are taking reinfusion. 
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q9a.Availability of stores * q4.Will you take reinfusion Cross tabulation 
   q4.Will you take 
reinfusion 
Total    yes no 
q9a.Availability of 
stores 
Excellent Count 15 9 24 
Expected Count 15.0 9.0 24.0 
% within 
q9a.Availability of 
stores 
62.5% 37.5% 100.0% 
Good Count 43 11 54 
Expected Count 33.8 20.2 54.0 
% within 
q9a.Availability of 
stores 
79.6% 20.4% 100.0% 
Neutral Count 15 14 29 
Expected Count 18.1 10.9 29.0 
% within 
q9a.Availability of 
stores 
51.7% 48.3% 100.0% 
Bad Count 2 11 13 
Expected Count 8.1 4.9 13.0 
% within 
q9a.Availability of 
stores 
15.4% 84.6% 100.0% 
Total Count 75 45 120 
Expected Count 75.0 45.0 120.0 
% within 
q9a.Availability of 
stores 
62.5% 37.5% 100.0% 
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Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 20.510
a
 3 .000 
Likelihood Ratio 21.096 3 .000 
Linear-by-Linear Association 
10.312 1 .001 
N of Valid Cases 120   
a. 1 cells (12.5%) have expected count less than 5. The minimum expected count is 4.88. 
Here P value is less than .05. Hence we can reject null hypothesis and can denote that there is 
significant association between responses to „availability of the stores‟ and „decision of whether 
to take reinfusion‟. From the bar chart below we can exemplify that those who think availability 
of the stores is good, have the tendency of desire for taking reinfusion more than that of other 
feelings towards „availability of the stores‟. 
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PART SEVEN: FINDINGS 
7.1 Findings 
So by the impression of all the statistical tests done above we can state that:  
 Women tend to suffer from osteoporosis more than that of men. As a result, it has been 
seen that Most of the patients are female. 
 Patients who believe in efficacy and feasibility of Aclasta they tend to take reinfusion 
more than that of who don‟t believe. 
 Patients who think Aclasta as the most effective drug for osteoporosis they are prone to 
be more loyal towards Aclasta even if they switch to another doctor. 
 Patients, who remember their reinfusion date, tend to go for reinfusion. 
 We also observe that many patients who are not happy with the pricing of Aclasta, still 
goes for reinfusion. Patients who are okay with high pricing of Aclasta, majority of them 
are taking reinfusion. But there are some patients who despite being okay with high 
pricing, not going for reinfusion as they have cured after very first infusion. 
 Patients who are happy with first infusion are the highest number of people to go for 
reinfusion. Significant numbers of patients are also taking reinfusion in accordance with 
doctors‟ prescription regardless of their physical condition after first infusion. There are 
40% of patients within „non improved health condition after first infusion‟ category, who 
go for reinfusion. 
 Patients who remember their reinfusion date are also happy with the discounting process 
 Doctor‟s visit amount has no impact on the decision made by patients regarding whether 
to go for reinfusion or not. 
 Patients have the tendency of abiding by doctors‟ prescription. 
 Even though the price is high, most patients will still go for reinfusion‟s who think high 
pricing is only the obstacle towards continuation. Patients who tend to forget their 
reinfusion date, most of them are prone to take reinfusion. Patients who would stop 
reinfusion when they will cure, among them majority is not going for reinfusion as they 
are absolutely fine after Aclasta infusion. Patients who are dissatisfied with Aclasta are 
not going for reinfusion.  
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 Patients‟ compliance rate with „money doesn‟t matter until health is concerned‟ is more 
than that of „Discount offer prompts them to buy Aclasta‟. 
 Compliance with high or low pricing has no effect on patients‟ decision making 
regarding reinfusion. 
 Dissatisfaction with the doctor has no effect on building loyalty towards Aclasta ignoring 
doctor‟s prescription. 
 Patients‟ loyalty towards continuation with Aclasta despite switching doctor some what 
depends on the kind of response or liking patients impose on Aclasta. There are some 
patients who are not appreciating the discounting process that much but still would be 
loyal because of Aclasta‟s high efficacy. 
 The more the favorable responses towards „availability of Aclasta stores‟ exist, the more 
there is tendency of the patients to take the decision of going for reinfusion. 
 Health condition after first infusion determines the perceived benefit emitted from 
Aclasta. Improved condition after first infusion certainly strengthens the patients‟ 
positive notion and perceived benefit stemming from the Aclasta. 
 
 
 
 
 
  
 
Note: Bar-diagrams of the findings are attached as Appendix 2. 
7.2 Recommendation: 
 Price is an ample obstacle to keep patients aloof from taking Aclasta even though these 
patients believe in Aclasta‟s efficacy to their utmost. Price can be lowered for the 
penniless patients through more lucrative discount schemes. 
Hence by checking above findings we can say that the patients who take 
Aclasta reinfusion, most of them are influenced by the satisfaction with 
Aclasta.  So we can reject null hypothesis stated at the very beginning of 
the Primary data Analysis and demonstrate that patients who go for 
reinfusion are actually satisfied with Aclasta. 
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 Novartis can arrange discount offer for their enlisted patients who have already infused 
once. So that the patients would more likely to be induced to infuse Aclasta
®
 for the next 
time as the medicine is to infuse once a year for three consecutive years.  
 Repetitive programs of Aclasta® in different hospitals can reinforce the doctors to 
prescribe it more frequently.  
 Patients have to be brought to hospital to get the Aclasta infusion which is quite 
ponderous for the aged patients. Hence arrangement of the infusion can be orchestrated at 
home of the patients just like home delivery. 
 More awareness program highlighting Aclasta should be boosted and reinforced. They 
can also enroll in social event sponsorship and the like. 
 
PART EIGHT: CONCLUSION 
 
Aclasta is undoubtedly the most effective drug for curing osteoporosis. This is the drug which 
comes from Abroad with intrinsic and chaste quality ensured. That‟s why the drug costs higher 
than other substitutes and competitors‟ products. But sometimes patients‟ age and having other 
lethal diseases may overshadow Aclasta‟s effectiveness. Novartis is boosting their campaign 
proclaiming Aclasta‟s value and its commitment to patients. Patients‟ health update (After 
taking Aclasta) is always gathered by the Call Center Service in Novartis drug. Sustaining 
agreeable rapport with patients- is the main motto for Novartis. Selling products to patients is 
not all for Novartis. Post purchase proclivity of the patients is also brought under custody. 
Patients‟ health condition, their appeal for discount is also overseen after Novartis sells the 
drug. Novartis also enlightens patients with education regarding their diseases, how Aclasta and 
other drugs work and also make them informed regarding the consequences beforehand. 
Novartis is not contended in merely healing patients, they are also working to allay the adverse 
side effects and ache; and trying to ascertain that patients feel snug and hazard free while taking 
Aclasta. Hence ultimate satisfaction of the patients is the most substantial and prior aim of 
Novartis. 
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 Appendix: 01 
QUESTIONNAIRE 
Q1.Feelings after taking Aclasta- 
 Feeling Well 
 Not feeling well 
 
Q2. I am taking Reinfusion- 
 Because I am happy with first Infusion 
 Because doctor has prescribed 
 Because of not much improvement of health I have gone for re-infusion 
 Haven't gone for re-infusion 
 
Q3.I won’t go for re-infusion- 
 Because price is so high that even after being satisfied can’t take 
 I am feeling well, hence don't feel the necessity to take it 
 Doctor has not 
 I have switched to another substitute 
 I am dissatisfied after taking first Infusion 
 Forgot about the reinfusion date 
 scared of the side effects 
 
Q4.Will you take reinfusion- 
 Yes  
 No 
 
Q5.Are you interested to attend Aclasta Patient Meeting? 
 Yes 
 No 
 May be 
  
Q6. Gender- (To find out who takes more doctors’ visit) 
 Male 
 Female 
 
Q7.Any perceived benefit have you found from Aclasta over competitors or substitutes? 
(If you have switching experience) 
 Yes 
 No 
  Same 
 I don't know 
 
Q8a. Aclasta is the most effective drug for osteoporosis 
 
Q8b. Money doesn't matter as long as the health is concerned 
 
Q8c.  Discounts Prompts us to buy Aclasta 
 
Q8d. High pricing is justified as Aclasta is brought from abroad and its effectiveness is 
quite high unless patents have other major health diseases   
 
 Agree 
 Undecided 
 Don’t agree 
 
Q9a.Availability of stores 
 Excellent 
 Good 
 Neutral 
 Bad 
Q9b.Awareness of Aclasta 
Q9c. Discounting process/ procedure 
 Excellent 
 Good 
 Neutral 
 Bad 
 Very bad 
 
Q10.Do you remember your reinfusion date? 
 
Q11. I don't take Aclasta infusion/reinfusion as I am dissatisfied with my doctor  
 
Q12.Being aware of Aclasta reinfusion I would/have gone for reinfusion ignoring my 
doctor's prescription 
 
 Q13.I have switched to another doctor, but still continuing with Aclasta reinfusion 
 True 
 False 
 Appendix: 02 
Findings: 
1. Feelings after taking Aclasta- 
 Feeling Well 
 Not feeling well 
 
 
 
2. Will you take reinfusion? 
 Yes  
 No 
 
 
 
87
33
Feelings after taking Aclasta
feeling well
not feeling well
75
45
Will you take re-infusion?
Yes No
 3. I am taking Reinfusion- 
 Because I am happy with first Infusion 
 Because doctor has prescribed 
 Because of not much improvement of health I have gone for re-infusion 
 Haven't gone for re-infusion 
 
 
 
Q5.Are you interested to attend Aclasta Patient Meeting? 
 
 
 
40
24
15
41
I am taking re-infusion
Because I am happy with 
first Infusion
Because doctor has 
prescribed
Because of not much 
improvement of health I 
have gone for re-infusion
Haven't gone for re-
infusion
52
40
28
Are you interested to attend aclasta 
patient meeting? 
Yes
No
May be
 I won’t go for re-infusion- 
 
 
Pays doctors visit-  
 Male 
 Female 
 
 
21
25
24
7
10
19
14
I won't go for re-infusion because-
Because price is so high 
that even after being 
satisfied can’t take
I am feeling well, hence 
don't feel the necessity to 
take it
Doctor has not precribed
I have switched to 
another substitute
I am dissatisfied after 
taking first Infusion
Forgot about the 
reinfusion date
scared of the side effects
45
75
Pays more amount of doctor's visit
Male
Female
 Any perceived benefit have you found from Aclasta over competitors or substitutes? 
(If you have switching experience) 
 Yes 
 No 
 Same 
 I don't know 
 
 
 
a. Money doesn't matter as long as the health is concerned 
b. Discounts Prompts us to buy Aclasta 
 
 
 
 
75
4
15
26
Any perceived benefit you have found from 
Aclasta over competitors or substitutes?
yes
no
same
I don’t know
22
17
81
Money doesn't 
matter as long as 
the health is 
concerned
Discounts 
Prompts us to 
buy Aclasta
can't decide
 High pricing is justified as Aclasta is brought from abroad and its effectiveness is quite 
high unless patents have other major health diseases   
 
 
 
 
Availability of stores 
 
 
 
 
 
 
 
 
47
33
33
High price is justified for Aclasta
agree
undecided
don't agree
24
54
29
13
Availability of Stores
Excellent
Good
Neutral
Bad
 Discounting process/ procedure 
 
 
 
Do you remember your reinfusion date? 
 
 
 
 
 
 
5
38
48
26
3
Discounting Process of Aclasta
Excellent
Good
Neutral
Bad
Very bad
6060
Do you remember your re-infusion date?
Yes
No
 I have switched to another doctor, but still continuing with Aclasta reinfusion 
 True 
 False 
 
46
74
I have switched to another doctor but still 
continuing with Aclasta 
Yes 
No
